FILTERED RESULTS
FILTERS
Ads Top
DARK MODE
CHART
    Filters
      Symbols
      Sentiment
      Impact
      Search
      FILTERED RESULTS

        

      Upgrade your plan
      ·

      gild

      ·

      Gilead Sciences to Acquire Tubulis for $5 Billion

      Gilead Sciences has announced its agreement to acquire Tubulis, a biotechnology company specializing in antibody-drug conjugates (ADCs), for a total of $5 billion. The deal includes an upfront payment of $3.15 billion, with additional payments contingent on achieving certain milestones.

      This acquisition is part of Gilead's strategy to enhance its oncology pipeline and bolster its research capabilities in cancer treatments. Tubulis's expertise in ADC technology is expected to complement Gilead's existing portfolio and accelerate the development of new therapies for cancer patients.

      © 2026 KLEA News. All Rights Reserved. This article is provided for informational purposes only. It is not offered or intended to be used as legal, tax, investment, financial, or other advice.

      Source: KLEA News

      .

      Terra Founder Do Kwon Sentenced to 15 Years in Prison for Fraud